𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗜𝗤𝗩𝗜𝗔’𝘀 𝗹𝗮𝘁𝗲𝘀𝘁 𝗿𝗲𝗽𝗼𝗿𝘁 𝗼𝗻 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗵𝗮𝗿𝗺𝗮 𝗥&𝗗 𝘁𝗿𝗲𝗻𝗱𝘀! In 2024, novel trial designs were used in 19% of trials, and in oncology, 25% of studies incorporated these innovative approaches. This growing adoption reflects the industry’s commitment to smarter, faster, and more patient-centric development. At PhaseV, we’re proud to be part of this evolution — empowering sponsors to design and run innovative, adaptive, Bayesian and data-driven trials that unlock new levels of efficiency and insight. Read more in IQVIA’s report and see how innovation in trial design is reshaping the future of R&D. #ClinicalTrials #RDInnovation #AdaptiveDesign #PhaseV #Pharma #Oncology #AI #ML #ClinicalDevelopment #Bayesiandesign https://lnkd.in/eqZkYqiY
PhaseV
Biotechnology Research
Boston, Massachusetts 5,270 followers
Adaptive. Causal. Intuitive.
About us
PhaseV is a Boston-based technology company transforming clinical development with an enterprise-ready AI/ML platform that accelerates decisions, de-risks trials, and drives portfolio efficiency. Its Trial Optimizer designs smarter studies, reducing costs by up to 50%, lowering enrollment needs by 40%, shortening timelines by 40%, and boosting probability of success by 30%+. The ClinOps Optimizer enhances site selection by integrating patient-level insights with real-time dashboards to track performance. The Lifecycle Management module combines causal evidence, development complexity, and market value to inform portfolio decisions. Together, these solutions enable sponsors and CROs to optimize every stage of development.
- Website
-
https://www.phasevtrials.com/
External link for PhaseV
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
200 Portland St
Boston, Massachusetts 02114, US
-
Get directions
Igal Alon 114
Tel Aviv, IL
Employees at PhaseV
Updates
-
We're excited to join Zoran Antonijevic and the Bioforum the Data Masters team to present Project Optimus! Brad Carlin, our Senior Director of Biostastics will be sharing his thoughts and a case study leveraging our AI-enabled Trial Optimizer for developing robust, cost-effective adaptive designs. PhaseV #ClinicalTrial #ClinicalDevelopment #TrialOptimizer #AdaptiveDesign #AI #ML
💡 Optimizing Dose, Accelerating Success: What Sponsors Must Know About Project Optimus Join Bioforum The Data Masters and our partner PhaseV for a live webinar on how Project Optimus is transforming oncology dose selection — from maximum tolerance to optimal efficacy and safety. Featuring Zoran Antonijevic, Chief Scientific Officer at Bioforum The Data Masters, and Brad Carlin, PhD, Senior Director of Data Science and Statistics at PhaseV. Learn how smarter study designs, simulations, and AI-driven strategies can help sponsors meet FDA expectations and accelerate submissions. 📅 November 12 | 11 AM EST 🔗 Register now: https://bit.ly/3JsiLvR #ProjectOptimus #Oncology #ClinicalTrials #Bioforum #PhaseV #DoseOptimization #AIinClinicalResearch
This content isn’t available here
Access this content and more in the LinkedIn app
-
PhaseV reposted this
𝗣𝗵𝗮𝘀𝗲𝗩 𝗖𝗮𝘂𝘀𝗮𝗹-𝗔𝗜 𝗽𝗼𝘄𝗲𝗿𝘀 𝗘𝗻𝗹𝗶𝘃𝗲𝘅’𝘀 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜𝗮 𝘀𝘁𝘂𝗱𝘆; 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝗮𝘁 𝗔𝗖𝗥 𝟮𝟬𝟮𝟱 We are proud to see our sponsor partner Enlivex Therapeutics (Nasdaq: ENLV) announce positive topline results from their Phase IIa 3-month data of Allocetra in patients with moderate-to-severe knee osteoarthritis. PhaseV was pleased to support this effort by helping optimize the study design through Trial Optimizer and perform heterogeneity analysis through Responder Optimizer. If you’re attending the American College of Rheumatology (ACR) Convergence 2025 this week, don’t miss Enlivex’s late-breaking poster presentation highlighting these results! Oren Hershkovitz Einat Galamidi #ClinicalTrials #AdaptiveDesign #AI #ML #Osteoarthritis #ACR2025 #TrialOptimizer https://lnkd.in/ewj3krsX
-
𝗣𝗵𝗮𝘀𝗲𝗩 𝗖𝗮𝘂𝘀𝗮𝗹-𝗔𝗜 𝗽𝗼𝘄𝗲𝗿𝘀 𝗘𝗻𝗹𝗶𝘃𝗲𝘅’𝘀 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜𝗮 𝘀𝘁𝘂𝗱𝘆; 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝗮𝘁 𝗔𝗖𝗥 𝟮𝟬𝟮𝟱 We are proud to see our sponsor partner Enlivex Therapeutics (Nasdaq: ENLV) announce positive topline results from their Phase IIa 3-month data of Allocetra in patients with moderate-to-severe knee osteoarthritis. PhaseV was pleased to support this effort by helping optimize the study design through Trial Optimizer and perform heterogeneity analysis through Responder Optimizer. If you’re attending the American College of Rheumatology (ACR) Convergence 2025 this week, don’t miss Enlivex’s late-breaking poster presentation highlighting these results! Oren Hershkovitz Einat Galamidi #ClinicalTrials #AdaptiveDesign #AI #ML #Osteoarthritis #ACR2025 #TrialOptimizer https://lnkd.in/ewj3krsX
-
𝗣𝗵𝗮𝘀𝗲𝗩 𝗻𝗮𝗺𝗲𝗱 𝘁𝗼 𝘁𝗵𝗲 𝟮𝟬𝟮𝟱 𝗗𝗶𝘀𝗿𝘂𝗽𝘁𝗼𝗿𝘀𝟲𝟬! We are incredibly honored to be named to the 2025 #Disruptors60 by @Greenfield Partners and live on @TechCrunch, alongside fellow innovators we respect across both AI infrastructure and applications. Chosen from nearly a thousand applicants, this recognition underscores our work that turns AI from promise into performance. For us, it is another validation that our causal AI platform helps biopharma sponsors and CROs design and execute more efficient clinical trials that identify responder faster and bring treatments to patients sooner. Thank you to the teams at TechCrunch and Greenfield Partners for the recognition, and to our customers and partners for their ongoing trust and support. See the full list of innovators here: www.disruptors60.ai #Disruptors60 #GreenfieldPartners #TCDisrupt #ClinicalDevelopment
-
-
PhaseV reposted this
Mission drives everything we do at PhaseV — but it’s exciting to see that work recognized! Honored to be included in CB Insights’ Digital Health 50: The most promising digital health startups of 2025. 👏
Congratulations to the Digital Health 50: The most promising digital health startups of 2025! 👏 This is CB Insights' 7th annual Digital Health 50 - their data-driven list of the world's highest-potential private companies in digital health. From clinical intelligence to revenue cycle management to patient communication, this year's winners are poised to define the next era of healthcare. 🚀 🌟 Administrative Operations 1m HealthEx Qualified Health Autonomize AI Infinitus Systems, Inc. Mandolin Plenful Sohar Health AssistIQ Arbital Health 🌟 Care Delivery Frontera Tele911 Sprinter Health Function Health Neko Health Isaac Health Sevaro Fay Nutrition Nourish Delfina 🌟 Clinical Workflow Automation Ambience Healthcare Freed Nabla CalmWave hellocare.ai Carta Healthcare Layer Health Atropos Health Guidehealth Hippocratic AI XUND 🌟 Diagnostics & Imaging PocDoc Teal Health Ataraxis AI Anumana Mendaera, Inc. Gestalt Diagnostics Rad AI 🌟 Drug Discovery & Development Persist AI PhaseV Variational AI Health Insurance Fortuna Health Thatch 🌟 Patient Communication & Engagement Assort Health Ellipsis Health Hyro Kouper Health 🌟 Senior Care August Health Inspiren SafelyYou Learn more about the companies who made the list this year 👉 https://lnkd.in/e_tTgu8Z
-
Roni Cohen, our Head of R&D and Engineering is taking the stage at Riverside today! Join her to explore her career path and the cutting-edge work we are doing at PhaseV. #Engineeringjourney #Leadership #ClinicalDevelopment #Networking
We're finally hosting our next meetup, and hopefully this October will be very different than the two previous Octobers 🙏 Our community members and engineering leaders, Roni Cohen and Shilo Magen, will share insights from their personal engineering leadership journeys, and as always, we will have some time for networking and mingling. Thank you Riverside for hosting us in their brand new offices! Daniel Korn Karni Wolf
-
-
𝐌𝐞𝐞𝐭 𝐔𝐬 𝐚𝐭 𝐇𝐋𝐓𝐇 𝟐𝟎𝟐𝟓 𝐢𝐧 𝐋𝐚𝐬 𝐕𝐞𝐠𝐚𝐬! We’re excited to join the world’s leading voices in healthcare innovation at HLTH 2025, taking place October 19-22 in Las Vegas! Join Carles Monterrubio, PhD, Director of Business Development at PhaseV, to explore how advanced analytics and evidence-based design are redefining clinical development. From streamlining execution to reducing cost and uncertainty, we enable teams to make smarter decisions and accelerate the path from discovery to patients. At HLTH, collaboration is everything: let’s connect and explore how smarter trial strategies can fuel the next wave of healthcare breakthroughs! 📩 Reach us at info@phasevtrials.com to set up a meeting. #PhaseV #HLTH2025 #HealthInnovation #ClinicalTrials #LifeSciences #DigitalHealth #PharmaInnovation #DrugDevelopment #HealthcareTransformation
-
Reminder: Our Webinar Is Tomorrow! ✨ Don’t miss your chance to join us tomorrow, October 14, 2025, at 10:00 AM EST for a deep dive into the FDA Draft Guidance on Overall Survival in Oncology Trials: What It Means for the Industry and How to Adapt. 🎙 Speaker: Brad Carlin, PhD, Senior Director of Data Science and Statistics at PhaseV It’s not too late to secure your spot - https://lnkd.in/eNENc4-Z
Upcoming Webinar Alert! Join us on Tuesday, October 14, 2025, at 10:00 AM EST for a must-attend session on: FDA Draft Guidance on Overall Survival in Oncology Trials: What It Means for the Industry and How to Adapt 🎙 Speaker: Brad Carlin, PhD, Senior Director of Data Science and Statistics at PhaseV What you’ll learn: ✔️ Key implications of the new FDA guidance for trial sponsors and statisticians ✔️ Preparing for enhanced OS-based patient safety requirements and interim analyses ✔️ Best practices for subgroup planning, sensitivity analyses, and regulatory alignment A live demo of PhaseV’s Trial Optimizer, showcasing how AI/ML can streamline trial design and execution This session is designed for biopharma leaders, clinical development teams, and biostatisticians preparing for the evolving oncological regulatory landscape. 🔗 Don’t miss out - Register here -https://lnkd.in/eNENc4-Z #FDA #OncologyTrials #ClinicalResearch #Biostatistics #PhaseV #LifeSciences #Webinar
-
-
PhaseV reposted this
✨ Reflecting on Fierce Biotech Week 2025 ✨ It was inspiring to be part of Fierce Biotech Week 2025 — a gathering that showcased how the industry is shaping the future of clinical research and patient care. I especially enjoyed the thought-provoking panel, “Innovation in Clinical Design and Management,” along side leaders from across the biopharma and healthcare landscape. The discussion highlighted how AI and digital tools are transforming clinical trials, making them more efficient, inclusive, and patient-centric than ever before. A special thank to the outstanding panelists for sharing their expertise and passion: Ariel Bourla, Head of Solid Tumor Oncology, Data Science & Digital Health, R&D – Johnson & Johnson Mridula Shukla, Sr. Director / Head of Genetic Medicines, Regulatory Affairs – Roche - Genentech Fatima Sabar CEO & Founder – Bluenote Dawn Lundin, Former Vice President of Global Quality – Lykos Therapeutics Kelli Wright, Director, Patient Advocacy – Day One Biopharmaceuticals And of course, having my wife, Daphna Patishi-Pryluk, by my side at the panel made the experience even more special :) At PhaseV, we are proud to be part of this movement, harnessing the power of advanced analytics to transform the design and execution of clinical trials, driving smarter, faster, and more cost-efficient studies. Hamza Sheikh Carles Monterrubio, PhD Jessica Petrochuk #FierceBiotechWeek #ClinicalInnovation #ClinicalTrials #DigitalHealth #AIinBiotech #AdaptiveDesign #DecentralizedTrials #PatientCentricity #PhaseV #Collaboration #FutureOfHealthcare
-